Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL

• Secondary Malignant Histiocytosis (SMH) is an exceedingly rare, life-threatening condition that invariably occurs in the presence of an underlying monoclonal hematologic disorder. Prognosis of SMH remains dismal and there is no established treatment. • We report a case of a patient who developed S...

Descripción completa

Detalles Bibliográficos
Autores principales: Abid, Muhammad Bilal, Wadhera, Karan, Bird, Jenny M., Pawade, Joya, Marks, David I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726878/
https://www.ncbi.nlm.nih.gov/pubmed/29264111
http://dx.doi.org/10.1016/j.lrr.2017.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726878/
https://www.ncbi.nlm.nih.gov/pubmed/29264111
http://dx.doi.org/10.1016/j.lrr.2017.11.003

Ejemplares similares